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Introduction
Ectopic Breast Tissue (EBT) is the most common congeni-
tal breast abnormality [1]. The occurrence of EBT ranges 
from 0,6% to 6% in the general population. Multiple theo-
ries have been proposed to explain the occurrence of acces-
sory breast. These include Darwin’s theory which stated that 
“traits which have disappeared generations before, can reap-
pear”; Pfeifer’s theory of metaplasia of sweat glands or modi-
fied sweat glands; Hughes’s theory of random migration of 
primordial breast cells away from the mammary crest, and 
Schultz’s theory of displacement of milk lines, laterally or 
caudally [2-5]. Despite morphological differences, EBT pres-
ents characteristics analogous to orthotopic breast tissue in 
terms of function and pathological degeneration. EBT comes 
in two forms: supernumerary and aberrant [6]. A supernu-
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merary breast consists of a ductal system communicating 
with the overlying skin, usually located along the ‘‘milk line’’, 
which extends from the axilla to the groin. It frequently re-
sponds to hormonal stimulation and undergoes physiologic 
changes as a complete functioning breast [7], is subject to the 
same diseases and alterations, whether benign or malignant, 
that affect orthotopic breasts [8,9]. Two varieties of super-
numerary breast should be distinguished: polymastia and 
polythelia. Polymastia (less than 1% of the population) is 
an accessory gland that occur as a consequence of the mam-
mary ridge failing to regress during embryonic development. 
The gland may be found in association with an areola-nipple 
complex. Polythelia (about 1,4% of the population) presents 
itself in the form of an areola and/or a nipple lacking glan-
dular tissue [10]. Aberrant breast, consists of an isolated 
fragment of glandular tissue located beyond the periphery 
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Abstract
Aims: Primary ectopic breast cancer (PEBC) is a rare and often misdiagnosed condition. Through the discussion of two clinical 
cases, we want to focus on clinical presentation, outcomes and treatment of PEBC, to lead clinicians to awareness and optimal 
management.
Methods: We present the case of a 47-year-old patient, with a 30 mm axillary mass, that was diagnosed as a PEBC (infiltrating 
lobular carcinoma, triple negative). The patient underwent systemic staging: diffuse metastatic bone lesions and leptomeningeal 
metastasis were found.
The second patient is a 73-year-old woman with personal history of right breast tumor. She came to our attention for a 9 mm left 
axillary mass, suspicious for a metastatic lymph node. A fine-needle cytology revealed the absence of lymphoid cells but the pres-
ence of atypical epithelial cells, as in a primary breast carcinoma. She was treated with local excision and sentinel node biopsy.
Results: The first patient presented with metastatic disease at the time of diagnosis and she deceased after three months from the 
diagnosis, despite systemic chemotherapy. The diagnosis was performed at an early stage in the second patient. She underwent 
surgery, complementary endocrine therapy and radiotherapy. She has no evident disease after two years from surgery.
Conclusion: Primary ectopic breast cancer is a rare clinical entity, often misdiagnosed or diagnosed with a long delay. The treat-
ment of PEBC is analogous to that of orthotopic breast cancer, but we strongly recommend to approach the patient with a multi-
disciplinary team to provide the best staging workout and therapies.
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of orthotopic breasts; it is characterized by an unorganized 
secretory system without any connection between the in-
side and the outside. The axilla is most frequently involved 
(70%) and the glandular tissue is located in the subcutane-
ous tissue and deep dermis [11]. Another 20% occurs in tho-
racic or abdominal portion of milk line, often on the left side 
of the body just below the inframammary crease [12]. EBT 
formation has also been found outside the galactic band that 
is in the face, posterior neck, midback, buttock, vulva, flank, 
hip, posterior and/or lateral thigh, shoulder and upper ex-
tremities [11]. This condition has also been associated with 
other congenital anomalies (nervous, cardiovascular, gas-
troenteric, skeletal, and, particularly, renal abnormalities) 
[8,13-15]. Data in the literature concerning the probability 
of malignant degeneration of EBT, and its management are 
scanty and controversial [10]. All articles regarding Primary 
Ectopic Breast Cancer (PEBC) are case reports and histori-
cal reviews. No systematic reviews or clinical trials are avail-
able. Given the rarity of this clinical condition, no specific 
guidelines are available in literature. Thus, early diagnosis 
and optimal management are still challenging for clinicians. 
The aim of this article is to describe two cases of breast can-
cer involving an EBT and to review the most recent litera-
ture.
Material and Methods
Patient 1: A 47-year-old Caucasian woman with familiar 
history of breast cancer, performing regular annual clini-
cal examination and mammography as part of the screen-
ing for SHBC patients. At clinical examination, a 30 mm hard 
mass was detected in the left axilla, with no evident com-
munication with the skin nor any structure referable to a 
nipple-areola-like complex (aberrant tissue). Imaging with 
mammography and high definition ultrasound revealed 
a hypo-echoic 25 mm mass, suspicious for a neoplasm on 
ectopic mammary gland. The radiological diagnosis was 
completed with breast MRI, which confirmed a 48×45 mm 
mass and an enlarged 20 mm lymph node. A core biopsy of 
the axillary suspicious mass was performed, and resulted in 
an infiltrative lobular carcinoma, triple-negative and MIB-1: 
12% (Figure 1). In the orthotopic left mammary gland two 
more nodular masses were found (diagnosed as C4 at a fine-
needle aspiration cytology) and a 14 mm lymph node was 
visible in the omolateral axilla. An interdisciplinary team 
approach recommended systemic staging with a thoraco-
abdominal CT scan, that showed diffuse metastatic bone 
lesions (sternum, hip bones, dorsal and lumbar vertebrae, 
femoral bone), confirmed by a bone scintigraphy.
Figure 1. H&E sections of lobular carcinoma in Patient 1.
Patient 2: A 73-year-old Caucasian woman with familiar 
history of breast cancer (a maternal aunt and three mater-
nal cousins at the age of 33, 70 and 75 with negative BRCA 
mutation test). She underwent right mastectomy with re-
constructive surgery and axillary lymphadenectomy two 
years before for a triple negative ductal infiltrative carci-
noma of the breast. Surgery was followed by adjuvant che-
motherapy with epirubicin and cyclophosphamide for four 
cycles and weekly paclitaxel for 12 administrations. Follow 
up was negative, until a 9 mm nodular lesion was detected 
by ultrasound in the left axillary cavity. The first clinical sus-
picion was for a metastatic lymph node even if the mass was 
in a subcutaneous position. A fine-needle aspiration cytol-
ogy was performed and revealed the presence of atypical 
epithelial cells, but no lymphoid cells were detectable. The 
diagnostic suspicion thus turned for a neoplasm of an ecto-
pic mammary gland, in its aberrant form. A breast MRI and 
a systemic re-staging with thoraco-abdominal CT scan were 
done and did not show any distant metastasis.
Results
Patient 1: The patient underwent systemic chemotherapy 
with FEC (fluorouracil, epirubicin and cyclophosphamide) 
for four cycles and simultaneous zoledronic acid, followed 
by Taxotere every three weeks. She also received radia-
tion therapy (3 Gy x 10 fractions) on the acetabulo-femoral 
joint and on ischio-pubic hip bone. At the end of the treat-
ment, a local restaging with breast MRI was performed and 
showed a reduction of the axillary mass (39×20 mm). The 
two smaller nodular masses were no longer detectable. The 
bone scintigraphy showed a downsizing of the metastatic 
bone lesions and no new metastatic lesions were visible on 
the thoraco-abdominal CT scan.
Seventeen days after the end of chemotherapy the patient 
presented nausea, vomiting, dizziness and vertigo. A brain 
CT scan without contrast medium was performed and did 
not show any brain lesion. The patient was treated with 
corticosteroid therapy with transitory reduction of symp-
toms. A few days after, temporal-spatial disorientation and 
headache appeared. The patient underwent a brain MRI 
with contrast medium, which showed the presence of lepto-
meningeal metastasis. The examination of the cerebrospinal 
fluid confirmed the diagnosis, showing multiple neoplastic 
epithelial cells. A supportive therapy was administered until 
the patient deceased, one month later.
Patient 2: An interdisciplinary team approach recommend-
ed wide local excision and sentinel node biopsy. The final 
pathological report revealed a grade 1 papillary carcinoma 
of the breast (Figure 2), with ER 98%, PgR 98%, Her-2 nega-
tive and MIB-1: 4%. Sentinel node was negative. The patient 
received both adjuvant endocrine therapy with Tamoxifen 
and external beam radiotherapy to whole residual breast 
and ipsilateral axillary region, until completing 50 Gy. She is 
in good clinical conditions with no evident disease after two 
years from surgery.
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Figure 2. H&E sections of papillary carcinoma in Patient 2.
Discussion
Both case reports present an opportunity to discuss clinical pre-
sentation, outcome and treatment of PEBC. Despite morpho-
logical differences EBT, whether supernumerary or aberrant, 
present characteristics analogous to orthotopic tissue in terms of 
function and pathological degeneration, including carcinoma 
[16,17]. PEBC is uncommon, accounting for 0,2 to 0,6 % of all 
breast cancers [12], but it has been reported in 60% to 70% of all 
forms of ectopic breast tumor. More frequently ectopic breast 
cancer is found in aberrant breast tissue, as it was in both the 
cases we presented. Clinical diagnosis is more challenging in 
aberrant tissue, because no visible anatomical structure (nipple-
areola complex) suggests the underlying presence of breast tis-
sue, as it is in complete supernumerary breast. Only a minority 
of patients develop breast cancer on a complete supernumerary 
breast. Some researchers consider malignant degeneration of 
EBT to be highly probable. In particular, aberrant breast tissue 
is reportedly more prone to malignant transformation than or-
thotopic or ectopic breast tissue [18,19], due to the stagnation in 
the ductal lumens which is considered a promoting factor for the 
development of malignancy [6]. It is no clear if PEBC has a 
race-prevalence as for BC. Some papers describe the highest 
incidence among Japanese and the lowest among Caucasians 
[11]. Familiar transmission account 10% of cases, as in the sec-
ond case report reported above [12]. PEBC seems to affect peo-
ple at a younger age compared to BC. However, PEBC shows a 
50 % peak of incidence between 40 and 45 years and a median 
age at diagnosis of 51 years [11]. There is a general belief that 
the risk factors for BC apply also to ectopic tissue. Clinical di-
agnosis is often delayed if not systematically considered in the 
differential diagnosis due to unfamiliarity with the condition, 
even in patients that regularly perform examinations for breast 
cancer familiar predisposition or in patients that already have a 
personal clinical history of breast cancer. The estimated delay in 
diagnosis is around 3.3 years. The presence of a subcutaneous 
mass along the milk line with clinical features of palpable mass, 
skin thickening, tenderness, or edema [20], should provoke a 
high suspicion for PEBC and this disease should be ruled out 
first [21]. Ultrasound is the first additional step: the presence of 
a hypo-echoic, not well-defined heterogeneous mass, without 
signs of inflammation, is suspicious [22]. Mammography may 
add further information even if micro calcifications of EBT are 
difficult to delineate [23,24]. The differential diagnosis of an 
axillary nodular mass must always include other subcutaneous 
masses such as fibroadenoma, lipoma, abscess, sebaceous cyst, 
hydradenitis or follicular cyst, haematoma, seroma, foreign 
body and lymphadenopathy associated with benign (mastitis, 
breast abscess, trauma, infection to upper extremity, tularemia, 
cat scratch disease, TBC, actinomicosis, etc) or malignant dis-
ease [19,25]. Particularly, PEBC should be included in the dif-
ferential diagnosis over metastatic nodes from chest and breast 
neoplasms, skin cancer, Hodgkin disease, adnexal malignant or 
soft tissue tumor. Therefore, in case of a unilateral axillary mass, 
breast, upper extremity and chest wall must always be accu-
rately checked. In case of a suspicious lesion, Fine-Needle As-
piration Biopsy (FNAB)/core biopsy of the axillary lump should 
be performed to harvest cells/tissue for histologic diagnosis 
[26]. If a PEBC is diagnosed, the regular work-up guidelines for 
BC should be followed. MRI (Magnetic Resonance Imaging) 
might be useful in defining the extension of the PEBC and its 
relationship with normal breast tissue before surgery [27] and 
for the best differential diagnosis between PEBC and occult pri-
mary breast cancer. Invasive ductal carcinoma Not Otherwise 
Specified (NOS) is the most common histotype both in ortho-
topic (40-75%) and ectopic breast tissue (72%) [9,25,28], fol-
lowed by invasive lobular carcinoma and medullary carcinoma 
(12%). Several pathological and immunohystochimic features 
can help to define the diagnosis: (1) Histologic pattern of a pri-
mary breast carcinoma in situ, (2) Presence of normal breast 
tissue surrounding the tumor, (3) Specific immunohistology for 
BC such as Estrogen and/or Progesteron receptors, and common 
breast markers such as Gross Cystic Disease Fluid Protein 
(GCDFP)-15. Although Her2/Neu, CEA and glandular keratins 
can be expressed in BC, they do not discriminate between a 
PEBC and a skin adnexal tumor, because they are not specific 
for the breast. Axillary node metastasis should be excluded too. 
The lymphatic spread of PEBC is most likely towards the ho-
molateral axillary nodes and from there towards the supracla-
vicular nodes, because this is the normal lymphatic drainage of 
the subcutaneous and cutaneous tissues of the armpit. Whether 
to consider the internal mammary lymph nodes as distant metas-
tasis instead of loco-regional involvement is still discussed and 
it affects systemic staging (M1 versus N1 or N2). When PEBC 
has been diagnosed, it is classified according to the TNM stag-
ing system used for primary breast carcinoma [24] and it should 
be treated in the same way as orthotopic breast disease. As we 
described in our clinical reports, both oncological and surgical 
approaches must be considered as primary treatment, depending 
on the stage, the performance status of the patient and the histo-
pathological features of the tumor. The role of Sentinel Node 
Biopsy (SNB) for PEBC of the axilla is not clear. The general 
trend has been to perform axillary clearance in all patients. 
However, in our second case report, after multidisciplinary dis-
cussion, the patient underwent sentinel node biopsy just to avoid 
a needless axillary clearance. Prognosis of accessory breast car-
cinoma is difficult to ascertain due to its rarity. Poor outcomes 
compared to native breast cancer have been reported, which 
may relate to delayed diagnosis often until clinical symptoms 
are present [29]. A higher incidence of lymph node involvement 
compared with primary breast carcinoma in the native breast 
may also contribute to different outcomes [11]. The location of 
primary breast carcinoma in axillary breast tissue, closer to axil-
lary lymph nodes, has been linked theoretically to earlier nodal 
metastatic disease [30,31], but for example in our two cases we 
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found early distant metastasis in one case and no metastasis in 
the lymph node in the other. Although speculative, this may be 
explained by the fact that the growing of metastases is related to 
biologic properties of the tumor rather than to the anatomic 
properties of the localization [11]. No specific treatment proto-
col is available in the literature for axillary PEBC and, further-
more, there is no consensus on whether to excise the EBT pro-
phylactically, to prevent the malignancy [32,33]. Traditionally, 
the surgical approach of PEBC was more aggressive, justified 
by the limited knowledge of its biological behavior and by the 
paucity of adjuvant treatments available: surgeons performed 
either a local tumorectomy or an ipsilateral prophylactic mas-
tectomy. Cogswell and Czerny concluded that local excision 
combined with axillary dissection was the surgical procedure of 
choice [34]. Evans and Guyton suggested that radical or modi-
fied radical surgery offered no advantage over local excision 
combined with axillary dissection or radiation with respect to 
outcomes [35]. Nowadays, the conservative approach (local ex-
cision on primary tumor and complementary radiotherapy), is 
always considered as the first surgical choice when feasible. 
This behavior is in line with the one that is generally adopted in 
orthotopic breast treatment. Adjuvant treatments that had been 
found to be effective for BC were successfully applied to PEBC 
as well. Hormonal therapy, when appropriate, was an integral 
part of the treatment, as well. Adjuvant radiotherapy should be 
considered to optimize loco-regional control. A review of the 
literature offers no formal guidance on RT dose, fractionation, 
and treatment fields in this setting. Treatment fields have ranged 
from incorporating the tumor bed alone to inclusion of the ipsi-
lateral uninvolved breast, axilla and supraclavicular fossa, even 
in the absence of nodal metastases [36]. Since there is no clear 
benefit to irradiate homo-lateral anatomic breast it is not per-
formed systematically. Some authors report that it must be con-
sidered in cases of uncertainty between an axillary EBT or axil-
lary metastasis from unknown primary breast cancer [37]. A 
careful follow-up is essential because of the limited knowledge 
of this tumor.
Conclusion
Primary ectopic breast cancer is a rare clinical entity often mis-
diagnosed or diagnosed with a long delay, leading to a poorer 
prognosis as compared to native breast cancer. The problem 
stems in part from a general lack of awareness that ectopic/ac-
cessory breast tissues have potentially dangerous implications, 
often underestimated by patients and physicians. We recom-
mend to regularly include the possible sites of ectopic breast tis-
sue in clinical examination and in the presence of an abnormal 
mass, always consider malignant tumor on ectopic breast in the 
differential diagnosis. Equivocal lesions, including microcalci-
fication, should be considered suspicious until otherwise prov-
en, followed up with close surveillance and/or candidate for di-
agnostic assessment. As we described in our cases, the treatment 
of PEBC is analogous to that of orthotopic breast cancer, but we 
strongly recommend to approach the patient with a multidisci-
plinary team to provide the best staging workout and therapies.
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